Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee

Jonathon Charlesworth, Jane Fitzpatrick, Nirmala Kanthi Panagodage Perera, John Orchard, Jonathon Charlesworth, Jane Fitzpatrick, Nirmala Kanthi Panagodage Perera, John Orchard

Abstract

Background: There is no cure for knee osteoarthritis (KOA) and typically patients live approximately 30-years with the disease. Most common medical treatments result in short-term palliation of symptoms with little consideration of long-term risk. This systematic review aims to appraise the current evidence for the long-term (≥12 months) safety of common treatments for knee osteoarthritis (KOA).

Methods: Cochrane Database of Systematic Reviews, Medline and PubMed were systematically searched from 1990 to July 2017, inclusive. Inclusion criteria were 1) peer-reviewed publications investigating treatments for KOA referred to in the Australian Clinical Care Standard and/or Therapeutic Guidelines: Rheumatology 2) specifically addressing safety of the treatments 3) with ≥12 months of follow-up and 4) Downs and Black quality score ≥ 13.

Results: Thirty-four studies fulfilled the inclusion criteria. Lifestyle modifications (moderate exercise and weight loss), paracetamol, glucosamine, Intraarticular Hyaluronic Acid (IAHA) and platelet-rich-plasma (PRP) injections have a low risk of harm and beneficial ≥12 month outcomes. Although Nonsteroidal Anti-inflammatory Drugs (NSAIDs) provide pain relief, they are associated with increased risk of medical complications. Cortisone injections are associated with radiological cartilage degeneration at > 12 months. Arthroscopy for degenerative meniscal tears in KOA leads to a 3-fold increase in total knee arthroplasty (TKA). TKA improves primary outcomes of KOA but has a low rate of significant medical complications.

Conclusions: Given the safety and effectiveness of lifestyle interventions such as weight loss and exercise, these should be advocated in all patients due to the low risk of harm. The use of NSAIDs should be minimized to avoid gastrointestinal complications. Treatment with opioids has a lack of evidence for use and a high risk of long-term harm. The use of IAHA and PRP may provide additional symptomatic benefit without the risk of harm. TKA is associated with significant medical complications but is justified by the efficacy of joint replacement in late-stage disease.

Trial registration: PROSPERO International prospective register for systematic reviews; registration number CRD42017072809 .

Keywords: Exercise; Injections; Knee; Osteoarthritis; Surgery.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable.

Competing interests

The authors’ declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study selection flow diagram

References

    1. March LM, Bagga H. Epidemiology of osteoarthritis in Australia. Med J Aust. 2004;180(5 Suppl):S6–10.
    1. Australian Institute of Health and Welfare (AUS) Osteoarthritis. Canberra: Australian Institute of Health and Welfare; 2016.
    1. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken) 2013;65(5):703–711. doi: 10.1002/acr.21898.
    1. Australian Orthopaedic Association (AUS) Lay summary 2015 annual report hip and knee replacement: suppliment report 2015. Sydney: Australian Orthopaedic Association; 2015.
    1. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9. doi: 10.1186/2046-4053-4-1.
    1. Moher D, Tricco A. Issues related to the conduct of systematic reviews: a focus on the nutrition field. Am J Clin Nutr. 2008;88(5):1191–1199.
    1. Australian Commission on Safety and Quality in Health Care (AUS) Osteoarthritis of the knee clinical care standard. Sydney: Australian commission on safety and Quality in Health Care; 2017.
    1. Rheumatology Expert Group (AUS) Therapeutic guidelines: rheumatology - version 3. Melbourne: therapeutic guidelines limited. 2017.
    1. Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. doi: 10.1136/jech.52.6.377.
    1. Messier S, Loeser R, Miller G, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the arthritis, diet, and activity promotion trial. Arthritis Rheum. 2004;50(5):1501–1510. doi: 10.1002/art.20256.
    1. Nejati P, Farzinmehr A, Moradi-Lakeh M. The effect of exercise therapy on knee osteoarthritis: a randomized clinical trial. Med J Islam Repub Iran. 2015;29:186.
    1. Jenkinson C, Doherty M, Avery J, et al. Effects of dietary intervention and quadriceps strengthening exercises on pain and function in overweight people with knee pain: randomised controlled trial. BMJ. 2009;339:b3170. doi: 10.1136/bmj.b3170.
    1. Kawasaki T, Kurosawa H, Ikeda H, et al. Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. J Bone Miner Metab. 2008;26(3):279–287. doi: 10.1007/s00774-007-0813-5.
    1. Gersing A, Schwaiger B, Nevitt M, et al. Is weight loss associated with less progression of changes in knee articular cartilage among obese and overweight patients as assessed with MR imaging over 48 months? Data from the osteoarthritis initiative. Radiol. 2017;284(2):508–520. doi: 10.1148/radiol.2017161005.
    1. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee psteoarthritis. Arch Intern Med. 2002;162(18):2113. doi: 10.1001/archinte.162.18.2113.
    1. Reginster J, Deroisy R, Rovati L, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256. doi: 10.1016/S0140-6736(00)03610-2.
    1. Sawitzke A, Shi H, Finco M, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008;58(10):3183–3191. doi: 10.1002/art.23973.
    1. Temple A, Benson G, Zinsenheim J, et al. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28(2):222–235. doi: 10.1016/j.clinthera.2006.02.004.
    1. Sawitzke A, Shi H, Finco M, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459–1464. doi: 10.1136/ard.2009.120469.
    1. McAlindon T, LaValley M, Harvey W, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317(19):1967–1975. doi: 10.1001/jama.2017.5283.
    1. Raynauld J, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003;48(2):370–377. doi: 10.1002/art.10777.
    1. Benazzo F, Perticarini L, Padolino A, et al. A multi-Centre, open label, long-term follow-up study to evaluate the benefits of a new viscoelastic hydrogel (Hymovis(R)) in the treatment of knee osteoarthritis. Eur Rev Med Pharmacol Sci. 2016;20(5):959–968.
    1. Conrozier T, Mathieu P, Schott A, et al. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine. 2003;70(2):128–133. doi: 10.1016/S1297-319X(03)00005-8.
    1. Huskin J, Vandekerckhove B, Delince P, et al. Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy. Knee Surg Sports Traumatol Arthrosc. 2008;16(8):747–752. doi: 10.1007/s00167-008-0556-4.
    1. Jorgensen A, Stengaard-Pedersen K, Simonsen O, et al. Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis. 2010;69(6):1097–1102. doi: 10.1136/ard.2009.118042.
    1. Juni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007;56(11):3610–3619. doi: 10.1002/art.23026.
    1. Navarro-Sarabia F, Coronel P, Collantes E, et al. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011;70(11):1957–1962. doi: 10.1136/ard.2011.152017.
    1. Ozturk C, Atamaz F, Hepguler S, et al. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int. 2006;26(4):314–319. doi: 10.1007/s00296-005-0584-z.
    1. Vaquerizo V, Plasencia M, Arribas I, et al. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. Arthroscopy. 2013;29(10):1635–1643. doi: 10.1016/j.arthro.2013.07.264.
    1. Kearey P, Popple A, Warren J, et al. Improvement in condition-specific and generic quality of life outcomes in patients with knee osteoarthritis following single-injection Synvisc: results from the LOBRAS study. Curr Med Res Opin. 2017;33(3):409–419. doi: 10.1080/03007995.2016.1260533.
    1. Yan C, Chan W, Yuen W, et al. Efficacy and safety of hylan G-F 20 injection in treatment of knee osteoarthritis in Chinese patients: results of a prospective, multicentre, longitudinal study. Hong Kong Med J. 2015;21(4):327–332.
    1. Filardo G, Kon E, Pereira Ruiz M, et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc. 2012;20(10):2082–2091. doi: 10.1007/s00167-011-1837-x.
    1. Smith P. Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis: an FDA-sanctioned, randomized, double-blind, placebo-controlled clinical trial. Am J Sports Med. 2016;44(4):884–891. doi: 10.1177/0363546515624678.
    1. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med. 2012;15(7):422–428.
    1. Emadedin M, Ghorbani Liastani M, Fazeli R, et al. Long-term follow-up of intra-articular injection of autologous mesenchymal stem cells in patients with knee, ankle, or hip osteoarthritis. Arch Iran Med. 2015;18(6):336–344.
    1. Orozco L, Munar A, Soler R, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013;95(12):1535–1541. doi: 10.1097/TP.0b013e318291a2da.
    1. Vega A, Martin-Ferrero M, Del Canto F, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681–1690. doi: 10.1097/TP.0000000000000678.
    1. Fodor P, Paulseth S. Adipose derived stromal cell (ADSC) injections for pain management of osteoarthritis in the human knee joint. Aesthet Surg J. 2016;36(2):229–236. doi: 10.1093/asj/sjv135.
    1. Rongen J, Rovers M, van Tienen T, et al. Increased risk for knee replacement surgery after arthroscopic surgery for degenerative meniscal tears: a multi-center longitudinal observational study using data from the osteoarthritis initiative. Osteoarthr Cartil. 2017;25(1):23–29. doi: 10.1016/j.joca.2016.09.013.
    1. Brophy R, Gray B, Nunley R, et al. Total knee arthroplasty after previous knee surgery: expected interval and the effect on patient age. J Bone Joint Surg Am. 2014;96(10):801–805. doi: 10.2106/JBJS.M.00105.
    1. El-Galaly A, Haldrup S, Pedersen A, et al. Increased risk of early and medium-term revision after post-fracture total knee arthroplasty. Acta Orthop. 2017;88(3):263–268. doi: 10.1080/17453674.2017.1290479.
    1. Skou S, Roos E, Laursen M, et al. A randomized controlled trial of total knee replacement. N Engl J Med. 2015;373(17):1597–1606. doi: 10.1056/NEJMoa1505467.
    1. Ansari M, Pareek A, Johnson N, et al. Clinical outcome of total knee arthroplasty after prior microfracture: a matched cohort study. Orthopedics. 2017;40(3):e473–e478. doi: 10.3928/01477447-20170223-02.
    1. Brand CA, Harrison C, Tropea J, et al. Management of osteoarthritis in general practice in Australia. Arthritis Care Res. 2014;66(4):551–558. doi: 10.1002/acr.22197.
    1. Chou R, Turner J, Devine E, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop effectiveness and risks of long-term opioid therapy for chronic pain. Ann Intern Med. 2015;162(4):276–286. doi: 10.7326/M14-2559.
    1. Furlan A, Sandoval J, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–1594. doi: 10.1503/cmaj.051528.
    1. Volkow N, McLellan A. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–1263. doi: 10.1056/NEJMra1507771.
    1. DeMik D, Bedard N, Dowdle S, et al. Are we still prescribing opioids for osteoarthritis? J Arthroplast 2017. S0883–5403(17)30666–30666.
    1. Wright E, Katz J, Abrams S, et al. Trends in prescription of opioids from 2003–2009 in persons with knee osteoarthritis. Arthritis Care Res. 2014;66(10):1489–1495. doi: 10.1002/acr.22360.
    1. Basedow M, Williams H, Shanahan E, et al. Australian GP management of osteoarthritis following the release of the RACGP guideline for the non-surgical management of hip and knee osteoarthritis. BMC Res Notes. 2015;8:536. doi: 10.1186/s13104-015-1531-z.
    1. Bruyere O, Cooper C, Pelletier J, et al. A consensus statement on the European Society for Clinical and Economic Aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4 Suppl):S3–11. doi: 10.1016/j.semarthrit.2015.11.010.
    1. Cutolo M, Berenbaum F, Hochberg M, et al. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum. 2015;44(6):611–617. doi: 10.1016/j.semarthrit.2014.12.003.
    1. Sondergaard K, Weeke P, Wissenberg M, et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother. 2017;3(2):100–107.
    1. Bhatt D, Scheiman J, Abraham N, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008;52(18):1502–1517. doi: 10.1016/j.jacc.2008.08.002.
    1. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909. doi: 10.1136/bmj.j1909.
    1. Cancienne J, Werner B, Luetkemeyer L, et al. Does timing of previous intra-articular steroid injection affect the post-operative rate of infection in total knee arthroplasty? J Arthroplast. 2015;30(11):1879–1882. doi: 10.1016/j.arth.2015.05.027.
    1. McGarry J, Daruwalla Z. The efficacy, accuracy and complications of corticosteroid injections of the knee joint. Knee Surg Sports Traumatol Arthrosc. 2011;19(10):1649–1654. doi: 10.1007/s00167-010-1380-1.
    1. Aggarwal A, Sempowski I. Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature. Can Fam Physician. 2004;50:249–256.
    1. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;2:CD005321.
    1. Australian Bureau of Statistics (AUS) 4364.0.55.001 - National Health Survey: first results, 2014-15. Canberra: Australian Bureau of Statistics; 2016.
    1. Australian Bureau of Statistics (AUS) Snapshot of Australia: 2016 Census data summary. Canberra: Australian Bereau of Statistics; 2017.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever